

6/35
3/20/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 97,186-D)

In application of:

Moskal et al.

Serial No. 09/597,604

Filed: June 20, 2000

For: Methods for Detection and Treatment
of Diseases Using a Glycosyltransferase

Group Art Unit: 1633

TRANSMITTAL LETTER

VIA HAND DELIVERY BY SCHELLIN & ASSOCIATES
Asst. Commissioner for Patents
Washington, D.C. 20231

RECEIVED
MAR 19 2001
TECH CENTER 1600, 2900


Dear Sir:

In regard to the above identified application.

1. We are transmitting herewith the attached:
 - a) Supplemental Information Disclosure Statement;
 - b) PTO Form 1449 and 13 cited references;
 - c) Return postcard
2. With respect to fees:
 - a) No fee is required at this time.Please charge any underpayment or credit any overpayment our Deposit Account. No. 13-2490.

Date: March 14, 2001

Respectfully submitted.


Patrick J. Halloran
Registration No. 41,053

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 97,186-D)

RECEIVED

MAR 19 2001

TECH CENTER 1600 2900

In application of:

Moskal et al.

Serial No. 09/597,604

Filed: June 20, 2000

For: Methods for Prevention and Treatment
of Diseases Using a Glycosyltransferase

Group Art Unit: 1633

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

VIA HAND DELIVERY BY SCHELLIN & ASSOCIATES
Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.98, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are not enclosed since they were previously submitted in the parent application, serial number 08/969,437. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

U.S. Patent Documents

<u>Document Number</u>	<u>Date</u>	<u>Name</u>	<u>Class</u>	<u>Filing Date If appropriate</u>
5,972,928	10/26/99	Chatterjee		
5,910,570	06/08/99	Elhammer		
5,871,997	02/16/99	Rother		
5,871,990	02/16/99	Clausen		
5,869,035	02/09/99	Link		
5,849,991	12/15/90	d'Apice		

Foreign Patent Documents

<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Translation</u>
WO 00/11190	03/02/00		
WO 97/38109	10/16/97		
WO 95/24924	09/21/95		
EP 0 754 057 B1	06/28/00		


Other Documents:

1. Eddington, Stephen M., (April 1992), *Bio/Technology*, Vol 10, pp. 383-389.
2. Elhammer, et al, (July, 1984), *The Journal of Cell Biology*, Vol 98, pp. 327-331.
3. Gorelik, Elieser, et al (September, 1995), *Cancer Research*, Vol 55, pp. 4168-4173.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

Date: March 14, 2001

By:


Patrick J. Halloran
Reg. No. 41,053